Published in Hepatology on May 01, 2009
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis (2011) 2.96
TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell (2012) 2.60
Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology (2014) 2.34
Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med (2010) 1.84
Viral hepatocarcinogenesis. Oncogene (2010) 1.73
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med (2012) 1.71
Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol (2010) 1.56
Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis (2015) 1.51
New virologic tools for management of chronic hepatitis B and C. Gastroenterology (2012) 1.41
Hepatitis B infection: current concepts and future challenges. QJM (2012) 1.08
Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. Gut Liver (2016) 1.03
52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One (2013) 1.01
Pre-S deletion and complex mutations of hepatitis B virus related to young age hepatocellular carcinoma in Qidong, China. PLoS One (2013) 1.00
Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, China. PLoS One (2014) 0.98
Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in Qidong, China. PLoS One (2014) 0.95
Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection--results from a clinic-based longitudinal cohort. Eur J Cancer (2012) 0.94
Multilaboratory evaluation of real-time PCR tests for hepatitis B virus DNA quantification. J Clin Microbiol (2011) 0.93
The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. Natl Sci Rev (2014) 0.91
Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89
An intronic variant in the GRP78, a stress-associated gene, improves prediction for liver cirrhosis in persistent HBV carriers. PLoS One (2011) 0.88
The role of HBsAg levels in the current management of chronic HBV infection. Ann Gastroenterol (2014) 0.88
The inverse association of serum HBV DNA level with HDL and adiponectin in chronic hepatitis B infection. Virol J (2010) 0.87
Hepatitis B viral load affects prognosis of hepatocellular carcinoma. World J Gastroenterol (2014) 0.87
Does antiviral therapy reduce complications of cirrhosis? World J Gastroenterol (2014) 0.86
Current and future directions for treating hepatitis B virus infection. World J Hepatol (2015) 0.85
Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS One (2013) 0.85
Liver physiology and liver diseases in the elderly. World J Gastroenterol (2013) 0.84
Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ Open (2013) 0.84
Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. PLoS One (2012) 0.83
Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med (2011) 0.82
Core antigen expression is associated with hepatic necroinflammation in e antigen-negative chronic hepatitis B patients with low DNA loads. Clin Vaccine Immunol (2010) 0.81
Molecular functions of thyroid hormones and their clinical significance in liver-related diseases. Biomed Res Int (2013) 0.80
Relationship between hepatitis B DNA viral load in the liver and its histology in patients with chronic hepatitis B. Caspian J Intern Med (2015) 0.79
Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition. Oncotarget (2016) 0.79
New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol (2016) 0.79
Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China. BMC Health Serv Res (2012) 0.79
The Relationship of Diabetes and Smoking Status to Hepatocellular Carcinoma Mortality. Medicine (Baltimore) (2016) 0.79
Hepatocellular carcinoma and hepatitis B surface protein. World J Gastroenterol (2016) 0.79
Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. World J Hepatol (2015) 0.78
Novel approach to identifying the hepatitis B virus pre-S deletions associated with hepatocellular carcinoma. World J Gastroenterol (2014) 0.78
Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma. World J Gastroenterol (2016) 0.77
Association between metabolic factors and chronic hepatitis B virus infection. World J Gastroenterol (2014) 0.77
Influence of age and HBeAg status on the correlation between HBV DNA and hepatic inflammation and fibrosis in chronic hepatitis B patients. Dig Dis Sci (2012) 0.77
Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol (2017) 0.77
Downregulation of immunosuppressive environment in patients with chronic HBV hepatitis on maintained remission. Front Immunol (2015) 0.76
Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study. Virol J (2013) 0.76
Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci (2017) 0.75
SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B. Oncotarget (2017) 0.75
A model with combined viral and metabolic factors effectively predicts HBeAg status under long term entecavir therapy: a prospective cohort study. Virol J (2015) 0.75
Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients. Drug Des Devel Ther (2016) 0.75
Peritumoral small ephrinA5 isoform level predicts the postoperative survival in hepatocellular carcinoma. PLoS One (2012) 0.75
To treat or not to treat the "immunotolerant phase" of hepatitis B infection: A tunnel of controversy. World J Hepatol (2014) 0.75
Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. Medicine (Baltimore) (2016) 0.75
A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model. Hepat Mon (2016) 0.75
Toll like receptor7 polymorphisms in relation to disease susceptibility and progression in Chinese patients with chronic HBV infection. Sci Rep (2017) 0.75
Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study. J Int AIDS Soc (2017) 0.75
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology (2006) 6.67
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol (2010) 3.55
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis (2012) 3.22
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46
Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol (2013) 2.44
Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm (2008) 2.16
Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res (2007) 2.02
Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology (2010) 1.89
Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke (2010) 1.82
Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology (2010) 1.69
Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int (2009) 1.65
Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol (2013) 1.60
Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology (2011) 1.59
Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol (2011) 1.57
Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol (2006) 1.56
Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology (2013) 1.45
Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol (2010) 1.36
Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol (2007) 1.28
Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol (2011) 1.26
Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis (2007) 1.24
Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control (2003) 1.23
Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev (2009) 1.21
Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int (2012) 1.20
Cost of chronic hepatitis B infection in China. J Clin Gastroenterol (2004) 1.14
Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol (2010) 1.05
Global DNA methylation levels in white blood cells as a biomarker for hepatocellular carcinoma risk: a nested case-control study. Carcinogenesis (2012) 1.04
Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol (2005) 1.01
Epidemiology of virus infection and human cancer. Recent Results Cancer Res (2014) 0.96
Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991-2. Gut (2010) 0.95
211 G to a variation of UDP-glucuronosyl transferase 1A1 gene and neonatal breastfeeding jaundice. Pediatr Res (2011) 0.94
Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS One (2013) 0.93
Urinary 8-oxodeoxyguanosine, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Carcinogenesis (2006) 0.93
Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol (2004) 0.93
Urinary 15-F2t-isoprostane, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Carcinogenesis (2008) 0.93
Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3. Leuk Res (2012) 0.91
Polycyclic aromatic hydrocarbon- and aflatoxin-albumin adducts, hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Cancer Lett (2007) 0.88
Chronic hepatitis B infection and risk of atherosclerosis-related mortality: A 17-year follow-up study based on 22,472 residents in Taiwan. Atherosclerosis (2010) 0.88
Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. Ann Med (2004) 0.87
Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids Health Dis (2005) 0.87
Preeclampsia and the risk of bronchopulmonary dysplasia in VLBW infants: a population based study. PLoS One (2013) 0.86
A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol (2012) 0.86
96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic) (2010) 0.86
Global DNA methylation in a population with aflatoxin B1 exposure. Epigenetics (2013) 0.85
Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. Int J Cancer (2014) 0.85
Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS One (2013) 0.85
Association between obesity, hypertriglyceridemia and low hepatitis B viral load. Int J Obes (Lond) (2012) 0.84
Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care (2011) 0.84
Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. PLoS One (2012) 0.83
Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients with chronic hepatitis B. Clin Gastroenterol Hepatol (2011) 0.83
A hospital-based study of clinical and genetic features of Crohn's disease. J Formos Med Assoc (2011) 0.82
Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol (2004) 0.82
Lifetime risk of distinct upper aerodigestive tract cancers and consumption of alcohol, betel and cigarette. Int J Cancer (2014) 0.81
Distinct seromarkers predict different milestones of chronic hepatitis B progression. Hepatology (2014) 0.80
Hepatitis B management costs in France, Italy, Spain, and the United Kingdom. J Clin Gastroenterol (2004) 0.80
Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors. Am J Cardiol (2003) 0.80
Model to predict hyperbilirubinemia in healthy term and near-term newborns with exclusive breast feeding. Pediatr Neonatol (2012) 0.79
Mediation Analysis of Hepatitis B and C in Relation to Hepatocellular Carcinoma Risk. Epidemiology (2016) 0.79
Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology (2015) 0.79
Causal Mediation Analysis of Survival Outcome with Multiple Mediators. Epidemiology (2017) 0.75
Author reply: To PMID 23355498. Am J Epidemiol (2013) 0.75
Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. Medicine (Baltimore) (2016) 0.75